56 citations
,
August 2020 in “American Journal of Clinical Dermatology” This study concluded that the ClinRO and PRO measures, along with their photoguides, offer clear and meaningful assessments for patients with alopecia areata concerning eyebrow, eyelash, and nail appearance, as well as eye irritation.
2 citations
,
June 2024 in “Journal of the American Academy of Dermatology” This study evaluated the agreement between clinician and patient assessments of eyebrow and eyelash hair loss severity in adults with severe alopecia areata, using data from two phase 3 studies over 52 weeks.
8 citations
,
August 2024 in “Clinical and Experimental Dermatology” This review discusses the limitations of existing clinician-reported outcome measures for alopecia areata and emphasizes the need for a composite scoring system to better assess disease severity.
4 citations
,
October 2024 in “American Journal of Clinical Dermatology” This study found that ritlecitinib improved patient-reported outcomes related to hair growth in individuals with alopecia areata, with some experiencing clinically meaningful hair regrowth, although changes in emotional symptoms and activity limitations were minimal and similar across treatment groups.
May 2025 in “JEADV Clinical Practice” This study found that using calcipotriene and betamethasone dipropionate cream in a real-world setting significantly improved clinical outcomes and patient quality of life for adults with mild-to-moderate scalp psoriasis, especially among those with higher adherence, demonstrating high treatment satisfaction.